Clinical trials form the foundation of medical progress, yet they remain plagued by inefficiency and bureaucracy. The process of bringing life-saving treatments to market often takes years longer than necessary, caught in a web of documentation and administrative hurdles. Yet Sharon Kim, CEO of MPilotAI, is leveraging artificial intelligence to cut through the red tape that slows down medical breakthroughs, with a mission to get treatments to patients faster.
Cutting Through the Paperwork
Anyone who’s worked in pharmaceutical research knows the headache. Sharon doesn’t mince words about it. “Clinical trials are the backbone of drug development, but the process is often slow, complex, and incredibly resource-intensive,” she explains. We’re talking about smart people stuck doing busywork instead of science. The numbers are staggering when you look at where researcher time actually goes. “Researchers spend hours—sometimes weeks—on documentation, protocol writing, and endless revisions,” Sharon points out. This isn’t just inefficient—it’s actively harmful to progress. “Not only does this delay progress, it pulls critical thinkers away from what matters most: the science.”
Scientists didn’t go through years of specialized training to spend their days formatting documents and chasing approvals. Yet that’s exactly what happens in labs across the world. Sharon saw this waste of talent firsthand during her decade in the field. “I’ve spent over a decade working at the intersection of healthcare innovation and artificial intelligence,” she says. The frustration grew until she decided to build a solution.
MPilotAI – Creating Real-World Solutions
Sharon’s company isn’t just throwing AI at the problem and hoping for the best. They’ve built something specifically for this industry’s unique challenges. “At MPilotAI, we’ve built a proprietary AI platform specifically designed to streamline clinical trial design,” she explains. The key word here is “specifically”—this isn’t generic tech repurposed for healthcare.
The tools are practical, designed to fit into how researchers already work. “Using our secure web-based platform and Word add-in, trial documents—like protocols and CSRs—can be generated, managed, and refined with ease,” Sharon says.
Nobody wants to learn a completely new system, so they’ve made it work with the tools scientists already use. They’ve even created specialized help that works alongside researchers. “We’ve trained a custom chatbot on our extensive protocol database to assist researchers in real time,” she notes. And because this is healthcare, security isn’t optional. “Everything is hosted in a closed, secure environment—ensuring compliance, data integrity, and peace of mind.”
Shifting Focus to What Matters
Sharon isn’t just trying to save time—she’s trying to change what scientists spend time on. “My passion is transforming how we run clinical trials—making them smarter, faster, and more accurate,” she explains. At MPilotAI, they’re “not just building tools—we’re reimagining the future of drug development.”
The impact goes far beyond efficiency metrics. “This isn’t just about efficiency—it’s about impact,” Sharon insists. The ripple effects touch every part of the development pipeline. “When we reduce the burden of documentation, we accelerate the entire development pipeline. That means faster trials, quicker approvals, and ultimately—getting life-saving treatments to patients sooner.”
Many researchers worry that AI means replacing human expertise. Sharon takes the opposite view. “Our AI doesn’t replace human expertise—it amplifies it. We want researchers focused on discovery, not paperwork.”
Sharon’s vision for MPilotAI comes down to letting everyone do what they’re best at. “Our vision is simple: to provide the world’s best AI-powered trial design service so our clients can focus on what they do best—creating breakthrough medicines,” she says. For companies tired of watching their best talent get sucked into administrative black holes, MPilotAI offers a way out. As Sharon puts it: “If you’re ready to see what’s possible when innovation meets precision, we’d love to show you what MPilotAI can do.” The goal isn’t just better paperwork—it’s better medicine. When researchers can focus on discovery instead of documentation, patients win. And that’s a future worth building.
Connect with Sharon Kim on LinkedIn to learn how MPilotAI is transforming clinical trials.
